Skip to main content

Advertisement

Log in

Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome

  • Brief Report
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

Atypical hemolytic uremic syndrome (aHUS) in childhood is a rare disease associated with high morbidity and mortality. Most cases progress to end-stage renal failure. In approximately 50% of affected patients, mutations in genes encoding complement proteins are causative of the impairment in the regulation of the complement alternative pathway. This leads to deficient host cell protection and inappropriate complement activation on platelets and endothelial cells, particularly in the kidneys. Complement factor H (FH) heterozygosity induces unregulated activation of the membrane attack complex (MAC) C5b-9. Present therapeutic strategies for aHUS include lifelong plasmapheresis and renal dialysis. Unfortunately, kidney transplantation is frequently an unsatisfactory intervention due to the high rate of post-transplantation HUS recurrence, particularly in patients with FH mutation. Combined liver–kidney transplantation is also associated with poor outcome, mostly as a result of premature liver failure secondary to uncontrolled complement activation. Eculizumab is a complement C5 antibody that inhibits complement factor 5a (C5a) and the formation of the MAC. Thus, this antibody may be a promising new agent for patients with an aHUS undergoing kidney transplantation. We present the first case of a young patient with aHUS who received eculizumab as prophylactic treatment prior to a successful kidney transplantation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Noris M, Remuzzi G (2009) Atypical hemolytic-uremic syndrome. N Engl J Med 361:1676–1687

    Article  CAS  Google Scholar 

  2. Frémeaux-Bacchi V, Fakhouri F, Roumenina L, Dragon-Durey MA, Loirat C (2011) Atypical hemolytic-uremic syndrome related to abnormalities within the complement system. Rev Med Interne 32:232–240

    Article  CAS  Google Scholar 

  3. Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, Macher MA, Niaudet P, Guest G, Boudailliez B, Bouissou F, Deschenes G, Gie S, Tsimaratos M, Fischbach M, Morin D, Nivet H, Alberti C, Loirat C, French Society of Pediatric Nephrology (2007) Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol 18:2392–2400

    Article  CAS  Google Scholar 

  4. Kavanagh D, Richards A, Goodship T, Jalanko H (2010) Transplantation in atypical hemolytic uremic syndrome. Semin Thromb Hemost 36:653–659

    Article  CAS  Google Scholar 

  5. Zareba KM (2007) Eculizumab: a novel therapy for paroxysmal nocturnal hemoglobinuria. Drugs Today 43:539–546

    Article  CAS  Google Scholar 

  6. Zimmerhackl LB, Hofer J, Cortina G, Mark W, Würzner R, Jungraithmayr TC, Khursigara G, Kliche KO, Radauer W (2010) Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome. N Engl J Med 362:1746–1748

    Article  Google Scholar 

  7. Al-Akash SI, Almond PS, Savell VH Jr, Gharaybeh SI, Hogue C (2011) Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation. Pediatr Nephrol 4:613–619

    Article  Google Scholar 

  8. Mache CJ, Acham-Roschitz B, Frémeaux-Bacchi V, Kirschfink M, Zipfel PF, Roedl S, Vester U, Ring E (2009) Complement inhibitor eculizumab in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 4:1312–1316

    Article  CAS  Google Scholar 

  9. Larrea CF, Cofan F, Oppenheimer F, Campistol JM, Escolar G, Lozano M (2010) Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation. Transplantation 89:903–904

    Article  Google Scholar 

  10. Nürnberger J, Philipp T, Witzke O, Opazo Saez A, Vester U, Baba HA, Kribben A, Zimmerhackl LB, Janecke AR, Nagel M, Kirschfink M (2009) Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med 360:542–544

    Article  Google Scholar 

  11. Gruppo RA, Rother RP (2009) Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med 360:544–546

    Article  CAS  Google Scholar 

  12. Chatelet V, Frémeaux-Bacchi V, Lobbedez T, Ficheux M, Hurault de Ligny B (2009) Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome. Am J Transplant 9:2644–2645

    Article  CAS  Google Scholar 

  13. Figueroa JE, Densen P (1991) Infectious diseases associated with complement deficiencies. Clin Microbiol Rev 4:359–395

    Article  CAS  Google Scholar 

  14. Platonov AE, Vershinina IV, Kuijper EJ, Borrow R, Käyhty H (2003) Long term effects of vaccination of patients deficient in a late complement component with a tetravalent meningococcal polysaccharide vaccine. Vaccine 21:4437–4447

    Article  CAS  Google Scholar 

  15. Kotnik V, Luznik-Bufon T, Schneider PM, Kirschfink M (1997) Molecular, genetic, and functional analysis of homozygous C8 beta-chain deficiency in two siblings. Immunopharmacology 38:215–221

    Article  CAS  Google Scholar 

  16. Blanckaert K, De Vriese AS (2006) Current recommendations for diagnosis and management of polyoma BK virus nephropathy in renal transplant recipients. l. Dial Transplant 21:3364–3367

    Article  Google Scholar 

  17. Ståhl AL, Vaziri-Sani F, Heinen S, Kristoffersson AC, Gydell KH, Raafat R, Gutierrez A, Beringer O, Zipfel PF, Karpman D (2008) Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation. Blood 111:5307–5315

    Article  Google Scholar 

  18. Olie KH, Goodship TH, Verlaak R, Florquin S, Groothoff JW, Strain L, Weening JJ, Davin JC (2005) Posttransplantation cytomegalovirus-induced recurrence of atypical hemolytic uremic syndrome associated with a factor H mutation: successful treatment with intensive plasma exchanges and ganciclovir. Am J Kidney Dis 45:12–15

    Article  Google Scholar 

Download references

Acknowledgement

We thank Prof. Peter Zipfel for his review of the manuscript and the helpful comments.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Marcus Weitz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Weitz, M., Amon, O., Bassler, D. et al. Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome. Pediatr Nephrol 26, 1325–1329 (2011). https://doi.org/10.1007/s00467-011-1879-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-011-1879-9

Keywords

Navigation